» Articles » PMID: 33281730

Tau Filament Self-Assembly and Structure: Tau As a Therapeutic Target

Overview
Journal Front Neurol
Specialty Neurology
Date 2020 Dec 7
PMID 33281730
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Tau plays an important pathological role in a group of neurodegenerative diseases called tauopathies, including Alzheimer's disease, Pick's disease, chronic traumatic encephalopathy and corticobasal degeneration. In each disease, tau self-assembles abnormally to form filaments that deposit in the brain. Tau is a natively unfolded protein that can adopt distinct structures in different pathological disorders. Cryo-electron microscopy has recently provided a series of structures for the core of the filaments purified from brain tissue from patients with different tauopathies and revealed that they share a common core region, while differing in their specific conformation. This structurally resolvable part of the core is contained within a proteolytically stable core region from the repeat domain initially isolated from AD tau filaments. Tau has recently become an important target for therapy. Recent work has suggested that the prevention of tau self-assembly may be effective in slowing the progression of Alzheimer's disease and other tauopathies. Here we review the work that explores the importance of tau filament structures and tau self-assembly mechanisms, as well as examining model systems that permit the exploration of the mode of action of potential inhibitors.

Citing Articles

Temperature-Dependent Aggregation of Tau Protein Is Attenuated by Native PLGA Nanoparticles Under in vitro Conditions.

Paul P, Rathnam M, Khalili A, Cortez L, Srinivasan M, Planel E Int J Nanomedicine. 2025; 20:1999-2019.

PMID: 39968061 PMC: 11834738. DOI: 10.2147/IJN.S494104.


Multimer Detection System: A Universal Assay System for Differentiating Protein Oligomers from Monomers.

Jamerlan A, Shim K, Sharma N, An S Int J Mol Sci. 2025; 26(3).

PMID: 39940966 PMC: 11818661. DOI: 10.3390/ijms26031199.


Rapid iPSC inclusionopathy models shed light on formation, consequence, and molecular subtype of α-synuclein inclusions.

Lam I, Ndayisaba A, Lewis A, Fu Y, Sagredo G, Kuzkina A Neuron. 2024; 112(17):2886-2909.e16.

PMID: 39079530 PMC: 11377155. DOI: 10.1016/j.neuron.2024.06.002.


Neuroprotection of Cholinergic Neurons with a Tau Aggregation Inhibitor and Rivastigmine in an Alzheimer's-like Tauopathy Mouse Model.

Zadrozny M, Drapich P, Gasiorowska-Bien A, Niewiadomski W, Harrington C, Wischik C Cells. 2024; 13(7.

PMID: 38607082 PMC: 11011792. DOI: 10.3390/cells13070642.


Mathematical topology and geometry-based classification of tauopathies.

Sugiyama M, Kosik K, Panagiotou E Sci Rep. 2024; 14(1):7560.

PMID: 38555402 PMC: 10981734. DOI: 10.1038/s41598-024-58221-5.


References
1.
Frost B, Hemberg M, Lewis J, Feany M . Tau promotes neurodegeneration through global chromatin relaxation. Nat Neurosci. 2014; 17(3):357-66. PMC: 4012297. DOI: 10.1038/nn.3639. View

2.
Bednarski E, Lynch G . Cytosolic proteolysis of tau by cathepsin D in hippocampus following suppression of cathepsins B and L. J Neurochem. 1996; 67(5):1846-55. DOI: 10.1046/j.1471-4159.1996.67051846.x. View

3.
Abraha A, Ghoshal N, Gamblin T, Cryns V, Berry R, Kuret J . C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. J Cell Sci. 2000; 113 Pt 21:3737-45. DOI: 10.1242/jcs.113.21.3737. View

4.
Goedert M, Wischik C, Crowther R, Walker J, Klug A . Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci U S A. 1988; 85(11):4051-5. PMC: 280359. DOI: 10.1073/pnas.85.11.4051. View

5.
Gomez-Ramos A, Diaz-Hernandez M, Rubio A, Diaz-Hernandez J, Miras-Portugal M, Avila J . Characteristics and consequences of muscarinic receptor activation by tau protein. Eur Neuropsychopharmacol. 2009; 19(10):708-17. DOI: 10.1016/j.euroneuro.2009.04.006. View